603367.SH
Cisen Pharmaceutical Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 13.61
−3.48%Sep 15, 2026, 07:35 UTC
Cisen Pharmaceutical announced that it plans to permanently replenish working capital with the remaining balance of RMB 13.0958 million from the "BFS 'blow-fill-seal' integrated aseptic filling production line project" after the project's completion and closing; the matter has been approved by the company's 14th meeting of the fifth board of directors and will be submitted to the 2026 first extraordinary shareholders' meeting for review.
Source:Sep 14, 2026, 08:00 UTC
Shandong Chenxin Pharmaceutical's subsidiary Shandong Chenxin Fodu Pharmaceutical received a drug registration certificate from the National Medical Products Administration for loteprednol etabonate and tobramycin eye drops, the first generic version approved in China.
Source:Sep 7, 2026, 10:04 UTC
Chenxin Pharmaceutical announced an interim dividend for the first half of 2026 of 0.216 yuan per share (including tax), totaling 98 million yuan, based on total share capital of 453 million shares.
Source:Aug 24, 2026, 08:41 UTC
Chenxin Pharmaceutical announced a cash dividend of 0.216 yuan per share (tax included), totaling 97.795 million yuan (tax included).
Source:Aug 12, 2026, 04:37 UTC
Cisen Pharmaceutical and others established Jining Chenqi Biotechnology Co., Ltd., a new biotechnology company in Jining, China.
Source: